Should Babies Have Their Genomes Sequenced?
        
            By Anna Nowogrodzki, 
                MIT Technology Review
             | 07. 02. 2015
        
                    
                                    
                    
                                                                                                                                    
                                                                            
                              
    
  
  
    
  
          
  
      
    
             
  Untitled Document 
  
For 51 years, newborn babies have gotten a heel-prick test in which   their blood is screened for dozens of congenital disorders. Routine   newborn screening has basically eliminated the risk of death or   irreversible brain damage that some of these disorders can pose if they   are not identified right away.
 
  Now some researchers in Boston are trying to find out if genomic sequencing at birth would be as successful.
 
  The BabySeq project is the first randomized, controlled trial to   measure the harms and benefits of newborn genomic sequencing. One of   four NIH-funded projects granted a total of $25 million to examine   genomic sequencing in newborns, BabySeq recently enrolled its first four   subjects, three healthy babies and one baby from the neonatal ICU. The   researchers got the first baby’s genomic sequence data last week.
 
  The central question for this project is what will come of giving   genomic information to parents and their baby’s doctor. Will doctors   order more tests and interventions? Will those tests and interventions   make babies healthier? Or will they just waste money, or even end up   doing...
 
 
  
 
    
    
  
   
                        
                                                                                
                 
                                                    
                            
                                  
    
  
  
      Related Articles
    
  
          
  
  
  
  
  
  
      
            
                  
  
      
    
    
                
                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                           By Megan Molteni and Anil Oza,  STAT | 10.07.2025
                                                        
     
    
    
            For two years, a panel of scientific experts, clinicians, and patient advocates had been hammering out ways to increase community engagement in National Institutes of Health-funded science. When they presented their road map to the NIH Director Jay Bhattacharya last...
 
       
 
 
  
      
    
    
    
    
            Paula Amato & Shoukhrat Mitalipov
[OHSU News/Christine Torres Hicks]
On September 30th, a team of 21 scientists from Oregon Health & Science University (OHSU) published a significant paper in Nature Communications, with a scientifically accurate but, to many, somewhat abstruse headline:
Induction of experimental cell division to generate cells with reduced chromosome ploidy
The lead authors were Shoukhrat Mitalipov, recently described here as “a push-the-envelope biologist,” and his long-term colleague Paula Amato. (Recall that in July the pair had co-published with...
 
       
 
 
  
      
    
    
                
                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                           By Pam Belluck,  The New York Times | 10.17.2025
                                                        
     
    
    
            Before dawn on a March morning, Doug Whitney walked into a medical center 2,000 miles from home, about to transform from a mild-mannered, bespectacled retiree into a superhuman research subject.
First, a doctor inserted a needle into his back to...
 
       
 
 
  
      
    
    
                
                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                           By Julia Black,  MIT Technology Review | 10.16.2025
                                                        
     
    
    
            Consider, if you will, the translucent blob in the eye of a microscope: a human blastocyst, the biological specimen that emerges just five days or so after a fateful encounter between egg and sperm. This bundle of cells, about the size of...